Alterity Therapeutics Limited is a biopharmaceutical company incorporated in Australia on November 11, 1997, focused on developing therapeutic drugs to treat neurodegenerative diseases, currently focusing on Parkinsonian and other movement disorders ¹. The company's technology is based on a platform approach targeting the interrelationship of metals and proteins, with a chemical library of more than 1000 novel compounds ². The company operates in the biotechnology and pharmaceutical industries, which are subject to rapid and significant technological change, with competitors including major pharmaceutical companies, biotechnology firms, universities, and other research institutions ³.

The company's lead product candidate is ATH434, an oral iron chaperone that redistributes excess labile iron in the central nervous system, being developed for Multiple System Atrophy (MSA), a rare Parkinsonian disorder with no approved treatments addressing the underlying pathology ⁴. The company's competitive position is concentrated around ATH434, and any setback in its clinical development, regulatory strategy, manufacturing scale-up, financing, or commercialisation could materially harm the business ⁵. The company has a history of successfully raising funds via equity capital raisings, resulting in a strong cash position for the fiscal year ended June 30, 2026 ⁶.

The company generates revenue primarily through research and development activities, with no commercialized products to date ⁷. The company's business model relies on third-party contractors for manufacturing, as it lacks internal manufacturing capabilities and does not plan to acquire the infrastructure internally ⁸. The company's primary customer segments are not yet defined as it has not commercialized any products, but its target indications include MSA, Parkinson's disease, Friedreich's ataxia, and Alzheimer's disease ⁹.

ATH434 is the lead drug candidate, discovered in-house, and has been shown in preclinical animal studies to reduce the accumulation and aggregation of α-synuclein, a protein implicated in neurodegeneration ¹⁰. The company also has a preclinical program in Parkinson's disease and a discovery platform developing compounds from different chemical scaffolds ¹¹. PBT2, a former product candidate for Alzheimer's disease, was sub-licensed to Professor Colin Masters in March 2023, with the company entitled to future royalties of net sales ¹².

The company has a two-tier Translational Research program structure, with the first tier encompassing core new chemical entity design, synthesis, and characterization, and the second tier comprising translational animal modeling programs ¹³. The company's discovery research has established Structure-Activity Relationships within chemical moieties, and new compounds have been generated that retain functionality across diverse and novel chemical scaffolds ¹⁴. The company also invented next generation iron chaperones in 2019 and 2020 and next generation zinc ionophores in 2021, which are subject to composition of matter claims in patent families ¹⁵.

In January 2026, the company stated a key objective for 2026 was to finalise its regulatory strategy with the FDA and initiate clinical trial activities for Phase 3 in MSA by the end of the calendar year ¹⁶. In March 2026, the company disclosed positive FDA feedback on certain clinical pharmacology and non-clinical development elements of the program, and in April 2026, positive FDA feedback on certain chemistry, manufacturing, and control elements of the planned Phase 3 program ¹⁷. In June 2026, the company disclosed the successful outcome of its End-of-Phase 2 meeting with the FDA, achieving alignment on the key elements of its registrational Phase 3 program for ATH434 in MSA ¹⁸.

The company has incurred recurring losses since inception, including operating losses of $23.4 million and $12.1 million for the years ended June 30, 2026 and 2025, respectively, and an operating cash outflow of $22.5 million and $11.5 million, respectively, for such years ¹⁹. The company expects to continue incurring losses into the foreseeable future and will need to raise substantial additional capital to continue the development of its planned research and development programs ²⁰. The consolidated financial statements have been prepared assuming the company will continue as a going concern as a result of the funds raised during the financial year ²¹.

The company's management has not provided explicit quantitative revenue, margin, or EPS guidance for the upcoming period in the filing.

The primary growth vector is the planned Phase 3 development of ATH434 for MSA, with a key objective to initiate clinical trial activities by the end of the calendar year 2026 ²². The company has achieved alignment with the FDA on key elements of the registrational Phase 3 program, including positive feedback on clinical pharmacology, non-clinical development, and chemistry, manufacturing, and control elements ²³. The transition from Phase 2 to a pivotal Phase 3 program may require significant additional capital, expanded manufacturing readiness, larger and more complex clinical operations, and continued alignment with regulators ²⁴.

The company is also advancing its discovery platform, with a chemical library of more than 1000 novel compounds, and intends to continue to strengthen its intellectual property portfolio with new patents ²⁵. The company has a preclinical program in Parkinson's disease and has conducted a Natural History Study in MSA, which provided vital information on disease progression and enabled the selection of biomarkers suitable for identifying study participants for treatment studies ²⁶. The company's next generation iron chaperones and zinc ionophores are subject to composition of matter claims in patent families filed or earmarked for filing in commercially significant economies ²⁷.

The company's margin and cost outlook is not explicitly detailed in the filing, but the company has implemented cost containment and deferment strategies to maintain its viability ²⁸. The company expects to continue incurring losses into the foreseeable future, with operating losses of $23.4 million and $12.1 million for the years ended June 30, 2026 and 2025, respectively ²⁹.

The company's operational outlook involves reliance on third-party contractors for manufacturing, as it lacks internal manufacturing capabilities and does not plan to acquire the infrastructure internally ³⁰. The company has not been required to invest material amounts for capital expenditures since its development efforts have taken place at research facilities operated by institutions with which it has relationships, including laboratories leased from The University of Melbourne's Bio21 Molecular Science and Biotechnology Institute ³¹.

The company's capital allocation strategy includes raising additional equity funding to finance its planned research and development programs, with a strong cash position for the fiscal year ended June 30, 2026 ³². The company has not declared or paid cash dividends on its ordinary shares and does not expect to do so in the foreseeable future ³³. The company may issue up to 15% of its outstanding ordinary shares in any 12-month period without shareholder approval, subject to ASX listing rules ³⁴.

The company faces significant headwinds, including the need for substantial additional funding to support the planned Phase 3 development of ATH434, which may not be available on acceptable terms or at all ³⁵. The company's business depends substantially on the success of ATH434, and setbacks in the planned Phase 3 development could materially harm the business ³⁶. The company also faces risks related to reliance on research institutions for clinical trials, lack of internal manufacturing capabilities, and the failure to establish sales, marketing, and distribution capability ³⁷.

The company is operating in a period of economic uncertainty and capital markets disruption, significantly impacted by geopolitical instability, including military conflicts in the Middle East and between Russia and Ukraine ³⁸. Tariff policies and potential countermeasures could increase costs and disrupt the global supply chain, negatively impacting results of operations ³⁹. The company also faces risks related to healthcare reform measures and other statutory or regulatory changes that could adversely affect its business ⁴⁰.

Management's message to shareholders emphasizes the company's mission to develop therapeutic drugs for neurodegenerative diseases, with a focus on advancing ATH434 through Phase 3 development for MSA ⁴⁶. The key strategic priorities for the period ahead include finalising the regulatory strategy with the FDA, initiating clinical trial activities for Phase 3 in MSA by the end of the calendar year 2026, and continuing to strengthen the intellectual property portfolio ⁴⁷. Management has highlighted the successful outcome of the End-of-Phase 2 meeting with the FDA, achieving alignment on key elements of the registrational Phase 3 program, and the company's strong cash position for the fiscal year ended June 30, 2026 ⁴⁸. The company expects to continue incurring losses into the foreseeable future and will need to raise substantial additional capital to continue development of its planned research and development programs ⁴⁹.

For the fiscal year ended June 30, 2026, the company reported operating losses of $23.4 million, compared to operating losses of $12.1 million for the fiscal year ended June 30, 2025 ⁵⁰. The company's operating cash outflow was $22.5 million for the fiscal year ended June 30, 2026, compared to $11.5 million for the fiscal year ended June 30, 2025 ⁵¹. The company had a potential tax benefit related to gross tax losses carried forward of $204,972,054 as of June 30, 2026, compared to $187,632,492 as of June 30, 2025 ⁵². The company recorded other income of $3,610,016, $5,438,918, and $4,019,285 for the years ended June 30, 2026, 2025, and 2024, respectively, related to the R&D Tax incentive refundable tax offset ⁵³. The company's net loss per share was $0.01 for the fiscal year ended June 30, 2026, and $0.007 for the fiscal year ended June 30, 2025 ⁵⁴. The company had cash and cash equivalents of $9,127,370,686 as of June 30, 2026, compared to $2,683,471,567 as of June 30, 2025 ⁵⁵. The company's total assets were $3,250,009,092 as of June 30, 2026, compared to $2,868,466,372 as of June 30, 2025 ⁵⁶. The company's issued capital was $2,154,912,180 as of June 30, 2026, compared to $2,868,466,372 as of June 30, 2025 ⁵⁷. The company's ordinary shares outstanding as of June 30, 2026 were 217,508,862 ⁵⁸. The company's ADR ratio was adjusted from 600 shares per ADR to 12 shares per ADR on May 29, 2026, following a consolidation of issued capital of 50 ordinary shares into one ordinary share ⁵⁹.

The company's business depends substantially on the success of ATH434, its lead product candidate, and setbacks in the planned Phase 3 development could materially harm the business ⁴¹. The company will require substantial additional funding to operate its business and support the planned Phase 3 development of ATH434, and such funding may not be available on acceptable terms or at all ⁴². The company lacks internal manufacturing capabilities and relies on third parties, and delays in supplying or scaling clinical materials to required standards, including for any planned pivotal Phase 3 trial, could negatively impact the business ⁴³. The company has a history of operating losses, including operating losses of $23.4 million and $12.1 million for the years ended June 30, 2026 and 2025, respectively, and expects to continue incurring losses into the foreseeable future ⁴⁴. The company is subject to risks related to healthcare reform measures and other statutory or regulatory changes, including the Inflation Reduction Act of 2022, which authorizes the Department of Health and Human Services to set drug price caps for certain high-cost Medicare Part B and Part D drugs, with the first year of maximum price applicability beginning in 2026 ⁴⁵.